Catherine (Cath) McGowen is #hiring. Know anyone who might be interested?
Third Rock Ventures
Venture Capital and Private Equity Principals
Boston, MA 42,290 followers
About us
We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives. THE THIRD ROCK TEAM Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed. A FORMULA FOR INNOVATION We only invest in the best of those ideas. We are actively involved in the early stages of our companies’ development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence. We believe in the companies we launch and make big initial investments, often complemented by strategic alliances, to enable our companies to advance life-changing therapies, devices and diagnostics. By creating value for patients, we create value for our investors.
- Website
-
http://www.thirdrockventures.com
External link for Third Rock Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Partnership
- Founded
- 2007
Locations
-
Primary
Get directions
29 Newbury St.
3rd Floor
Boston, MA 02116, US
-
Get directions
499 Illinois St
San Francisco, California 94158, US
Employees at Third Rock Ventures
Updates
-
Third Rock Ventures reposted this
Biomarker's list of 24 rising stars in biotech investing and creation for 2024! In our interviews, we cover questions like: -How do you transition to biotech investing from an academic background? -Is there a mental checklist to identify promising investment opportunities? -Which skills make you a better biotech investor or creator? -Tips for #biotech entreprenuers pitching in 2024? Excited to publish this annual resource, which is intended for those considering an investing career, entrepreneurs looking for tips, or scientists/physicians with a healthy dose of curiosity. Thank you to the interviewees and firms for sharing their insights. #biomarker 24 rising stars: Alex Loftis, Alim Ladha, Artavazd Arumov, Aniqa Tasnim, Danjuma Q., David K. Yang, Harim Won, James Buxton M.D., Kevin Li, Lauren Mifflin, Nil Gural, Noelle Hutchins, PhD, Pablo Lubroth, Patrick Lundgren, Roman Camarda, Shoman Kasbekar, Suan Tuang, M.D., Ph.D., Travis Hughes MD, PhD, MPH, Sahil Chopra Amanda C. Rebecca Silberman, Jason Wang, Linda T. Vo, PhD Firms: 5AM Ventures, Atlas Venture, Digitalis Ventures, Foresite Capital, Frazier Life Sciences, Omega Funds, Qiming Venture Partners USA, New Enterprise Associates (NEA), Vida Ventures, LLC, Vertex Ventures HC, Third Rock Ventures, Novo Holdings, MPM BioImpact, RA Capital Management, Lux Capital, Hummingbird Ventures, Osage University Partners (OUP)
-
Congratulations to Arnav Mehta, MD PhD for receiving the 2024 NextGen Stars award from AACR. So well deserved!
-
-
We are excited to support this experienced team. Congratulations to Seaport Therapeutics on their launch!
We’re pleased to launch Seaport Therapeutics today with the closing of a $100 million oversubscribed Series A financing round, co-led by ARCH Venture Partners, Sofinnova Investments Investments, along with Third Rock Ventures and Seaport founder PureTech Health. Seaport is founded and led by a team of industry veterans that were involved in inventing and advancing KarXT and other neuropsychiatric medicines, including Daphne Zohar, Founder, CEO and Board Member, and Steven Paul, Founder and Chair of the Board of Directors. The financing will support the rapid advancement of Seaport’s clinical-stage pipeline of novel neuropsychiatry medicines in areas of high unmet patient needs. https://bit.ly/3TPnU2b
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
businesswire.com
-
Third Rock Ventures reposted this
April 10 at 6pm PT. We have another incredible Innovator’s Workbench event planned, featuring Ted W. Love, MD, chair of the board of the Biotechnology Innovation Organization. Innovation Fellowship alum Uday Kumar, a senior advisor at Stanford Biodesign, will chat with Dr. Love about his journey into biotechnology innovation and the need to take on large, complex challenges to drive greater health equity for all populations. Don’t miss it! Registration link in the comments. #innovationeducation #biotech #healthtech #healthequity
-
-
Congratulations to the Clasp Therapeutics team on their launch with a $150 million Series A. We are looking forward to the impact of Clasp’s innovative approach to potently and specifically eliminate tumor cells, and make a meaningful difference for cancer patients.
We are immensely excited to announce our official launch as a company, with $150M Series A financing. Clasp Therapeutics aims to expand the reach of immuno-oncology by creating novel precision medicines to help people with cancer live longer and healthier lives. We are developing unique antibody-like T cell engagers that can be matched to an individual’s immune system and their specific tumor’s genetics. By targeting the truncal driver mutations that lie at the root of cancer growth, we hope to give every patient the opportunity to respond to treatment. Clasp was born out of scientific advancements made by its founders at The Johns Hopkins University, including Bert Vogelstein and Drew Pardoll. The company is helmed by industry veteran Robert Ross. The financing was led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, with participation from Cure Ventures, Vivo Capital, Alexandria Real Estate Equities, Inc., Blackbird BioVentures, BrightEdge - American Cancer Society , and Pictet Group. The goal of our approach is to create a personalized, but off-the-shelf therapy, that enlists all types of a patient’s T cells to eradicate tumor cells with absolute specificity. For more information on today’s launch announcement, please see our press release: https://lnkd.in/eCGwcbDv You can learn more about Clasp by visiting our website here: www.clasptx.com #patients #cancer #immunooncology #TCellEngagers #oncology #precisionmedicine
-
-
We are delighted to announce the expansion of our senior team. Congratulations to Jigar Raythatha on his promotion to partner as well as Vyas Ramanan on his promotion to Venture Partner. Additionally, a big welcome to Mary Lynne Hedley, Steven Paul (welcome back!), & Courtney Wallace. https://lnkd.in/eXk_MadE
-
-
Congratulations to Synnovation Therapeutics on their launch with a $102 million Series A. We are excited to be a part of the efforts towards improving the care of cancer patients with a pipeline built around highly validated precision oncologic targets.
Today we announced the closing of $102 million in Series A funding, and the appointment of Jigar Raythatha of Third Rock Ventures and Thilo Schroeder, Ph.D. of Nextech Invest to our Board of Directors. We are appreciative for the support of our new and existing investors as we continue to work towards changing the lives of patients living with cancer. More in today’s release: https://lnkd.in/eTvuKwZp Third Rock Ventures, Nextech Ventures, Lilly Asia Ventures 礼来亚洲基金, Sirona Capital, Cormorant Asset Management, LP
News-SeriesA Launch | Synnovation Therapeu
synnovationtx.com
-
Third Rock Ventures reposted this
Today, Rapport is pleased to announce the appointment of Terry-Ann Burrell to our Board of Directors. Terry-Ann, who currently serves as CFO of Beam Therapeutics, has extensive experience in executive financial leadership. Prior to Beam, she was with J.P. Morgan for over a decade covering the biotechnology and pharmaceutical sectors and where she helped to execute a number of major financings. We welcome her to the Board! Read more in today’s release: https://lnkd.in/eiXg5beF
-